Cancer - New-wiki

Novel	Symbols	Name 1	Name 2	Pathways 1 Hide	Pathways 2 Hide	Drugs 1 Hide	Drugs 2 Hide	Diseases 1 Hide	Diseases 2 Hide
Novel Novel	Symbols ARRB2 and CDC42	Name 1 arrestin beta 2	Name2 cell division cycle 42	Pathway 1 Activated NOTCH1 Transmits Signal to the Nucleus G alpha (s) signalling events Thrombin signalling through proteinase activated receptors (PARs) WNT5A-dependent internalization of FZD4 Activation of SMO Activation of SMO MAP2K and MAPK activation Ub-specific processing proteases Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis Signaling downstream of RAS mutants Signaling by RAF1 mutants TGFBR3 regulates TGF-beta signaling	Pathway 2 GPVI-mediated activation cascade EGFR downregulation Regulation of actin dynamics for phagocytic cup formation Regulation of actin dynamics for phagocytic cup formation CD28 dependent Vav1 pathway EPHB-mediated forward signaling EPHB-mediated forward signaling DCC mediated attractive signaling Inactivation of CDC42 and RAC1 VEGFA-VEGFR2 Pathway Myogenesis Myogenesis RHO GTPases activate KTN1 RHO GTPases activate IQGAPs RHO GTPases activate PAKs RHO GTPases Activate WASPs and WAVEs RHO GTPases Activate WASPs and WAVEs RHO GTPases Activate Formins RHO GTPases Activate Formins MAPK6/MAPK4 signaling Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation G beta:gamma signalling through CDC42 CDC42 GTPase cycle RAC1 GTPase cycle RAC2 GTPase cycle RHOQ GTPase cycle RHOG GTPase cycle RHOJ GTPase cycle RHOU GTPase cycle RAC3 GTPase cycle RHOV GTPase cycle FCGR3A-mediated phagocytosis FCGR3A-mediated phagocytosis Factors involved in megakaryocyte development and platelet production	Drugs 1	Drugs 2 Aminophosphonic acid-guanylate ester Guanosine-5'-Diphosphate	Diseases 1	Diseases 2
Novel Novel	Symbols ARRB2 and BCAS1	Name 1 arrestin beta 2	Name2 brain enriched myelin associated protein 1	Pathway 1 Activated NOTCH1 Transmits Signal to the Nucleus G alpha (s) signalling events Thrombin signalling through proteinase activated receptors (PARs) WNT5A-dependent internalization of FZD4 Activation of SMO Activation of SMO MAP2K and MAPK activation Ub-specific processing proteases Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis Signaling downstream of RAS mutants Signaling by RAF1 mutants TGFBR3 regulates TGF-beta signaling	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols ARRB2 and CXCR4	Name 1 arrestin beta 2	Name2 C-X-C motif chemokine receptor 4	Pathway 1 Activated NOTCH1 Transmits Signal to the Nucleus G alpha (s) signalling events Thrombin signalling through proteinase activated receptors (PARs) WNT5A-dependent internalization of FZD4 Activation of SMO Activation of SMO MAP2K and MAPK activation Ub-specific processing proteases Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis Signaling downstream of RAS mutants Signaling by RAF1 mutants TGFBR3 regulates TGF-beta signaling	Pathway 2 Binding and entry of HIV virion Signaling by ROBO receptors Chemokine receptors bind chemokines G alpha (i) signalling events Formation of definitive endoderm Specification of primordial germ cells Developmental Lineage of Multipotent Pancreatic Progenitor Cells	Drugs 1	Drugs 2 Baclofen Framycetin AMD-070 Plerixafor Ulocuplumab Ibalizumab MSX-122	Diseases 1	Diseases 2 Chemokine receptor defect, including the following disease: WHIM syndrome
Novel Novel	Symbols CSF1R and FYN	Name 1 colony stimulating factor 1 receptor	Name2 FYN proto-oncogene, Src family tyrosine kinase	Pathway 1 Other interleukin signaling Transcriptional Regulation by VENTX Signaling by CSF1 (M-CSF) in myeloid cells	Pathway 2 GPVI-mediated activation cascade Signaling by ERBB2 PIP3 activates AKT signaling Signaling by SCF-KIT Signaling by SCF-KIT Regulation of KIT signaling Nef and signal transduction Cell surface interactions at the vascular wall FCGR activation PECAM1 interactions Constitutive Signaling by Aberrant PI3K in Cancer DAP12 signaling DAP12 signaling EPH-Ephrin signaling Role of LAT2/NTAL/LAB on calcium mobilization Nephrin family interactions Nephrin family interactions NCAM signaling for neurite out-growth NCAM signaling for neurite out-growth Co-stimulation by CD28 CD28 dependent PI3K/Akt signaling CD28 dependent Vav1 pathway Co-inhibition by CTLA4 EPHB-mediated forward signaling EPHB-mediated forward signaling EPHA-mediated growth cone collapse EPHA-mediated growth cone collapse Ephrin signaling Ephrin signaling EPH-ephrin mediated repulsion of cells Sema3A PAK dependent Axon repulsion SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion CRMPs in Sema3A signaling CRMPs in Sema3A signaling VEGFA-VEGFR2 Pathway Dectin-2 family CD209 (DC-SIGN) signaling RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Platelet Adhesion to exposed collagen Reelin signalling pathway Regulation of signaling by CBL Regulation of signaling by CBL FCGR3A-mediated IL10 synthesis FCGR3A-mediated phagocytosis Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by CSF1 (M-CSF) in myeloid cells FLT3 signaling through SRC family kinases Antigen activates B Cell Receptor (BCR) leading to generation of second messengers High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells	Drugs 1 Imatinib Sunitinib Linifanib 5-CYANO-FURAN-2-CARBOXYLIC ACID [5-HYDROXYMETHYL-2-(4-METHYL-PIPERIDIN-1-YL)-PHENYL]-AMIDE 6-CHLORO-3-(3-METHYLISOXAZOL-5-YL)-4-PHENYLQUINOLIN-2(1H)-ONE Fostamatinib Erdafitinib Pexidartinib	Drugs 2 Dasatinib Triglyme Fostamatinib Zotiraciclib	Diseases 1 Choriocarcinoma	Diseases 2
Novel Novel	Symbols CSF1R and SOS1	Name 1 colony stimulating factor 1 receptor	Name2 SOS Ras/Rac guanine nucleotide exchange factor 1	Pathway 1 Other interleukin signaling Transcriptional Regulation by VENTX Signaling by CSF1 (M-CSF) in myeloid cells	Pathway 2 SOS-mediated signalling SOS-mediated signalling Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants SHC1 events in ERBB2 signaling SHC1 events in ERBB4 signaling Signaling by SCF-KIT Regulation of KIT signaling Signalling to RAS Signalling to RAS GRB2 events in EGFR signaling SHC1 events in EGFR signaling Downstream signal transduction NRAGE signals death through JNK GRB2 events in ERBB2 signaling GRB2 events in ERBB2 signaling Tie2 Signaling EGFR Transactivation by Gastrin DAP12 signaling SHC-related events triggered by IGF1R SHC-related events triggered by IGF1R Role of LAT2/NTAL/LAB on calcium mobilization Role of LAT2/NTAL/LAB on calcium mobilization FCERI mediated MAPK activation FCERI mediated Ca+2 mobilization FCERI mediated Ca+2 mobilization GRB2:SOS provides linkage to MAPK signaling for Integrins NCAM signaling for neurite out-growth G alpha (12/13) signalling events Activation of RAC1 Constitutive Signaling by EGFRvIII SHC-mediated cascade:FGFR1 FRS-mediated FGFR1 signaling SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling SHC-mediated cascade:FGFR3 FRS-mediated FGFR3 signaling FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Signaling by FGFR3 in disease RAF/MAP kinase cascade Signal attenuation Insulin receptor signalling cascade Insulin receptor signalling cascade MET activates RAS signaling RET signaling Interleukin-15 signaling RAC1 GTPase cycle Activated NTRK2 signals through RAS Erythropoietin activates RAS Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK3 signals through RAS Interleukin receptor SHC signaling FLT3 Signaling Constitutive Signaling by Overexpressed ERBB2 Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants Potential therapeutics for SARS Signaling by CSF1 (M-CSF) in myeloid cells Signaling by FLT3 fusion proteins Signaling by FLT3 ITD and TKD mutants Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Signaling by LTK	Drugs 1 Imatinib Sunitinib Linifanib 5-CYANO-FURAN-2-CARBOXYLIC ACID [5-HYDROXYMETHYL-2-(4-METHYL-PIPERIDIN-1-YL)-PHENYL]-AMIDE 6-CHLORO-3-(3-METHYLISOXAZOL-5-YL)-4-PHENYLQUINOLIN-2(1H)-ONE Fostamatinib Erdafitinib Pexidartinib	Drugs 2	Diseases 1 Choriocarcinoma	Diseases 2 Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
Novel Novel	Symbols CSF1R and PIK3R1	Name 1 colony stimulating factor 1 receptor	Name2 phosphoinositide-3-kinase regulatory subunit 1	Pathway 1 Other interleukin signaling Transcriptional Regulation by VENTX Signaling by CSF1 (M-CSF) in myeloid cells	Pathway 2 PI3K Cascade IRS-mediated signalling GPVI-mediated activation cascade Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K events in ERBB4 signaling PIP3 activates AKT signaling Interleukin-7 signaling Interleukin-7 signaling Signaling by SCF-KIT Synthesis of PIPs at the plasma membrane GAB1 signalosome Signaling by cytosolic FGFR1 fusion mutants Downstream signal transduction PI3K events in ERBB2 signaling PI3K/AKT activation Signaling by ALK Downstream TCR signaling Role of phospholipids in phagocytosis Tie2 Signaling Constitutive Signaling by Aberrant PI3K in Cancer DAP12 signaling Role of LAT2/NTAL/LAB on calcium mobilization Nephrin family interactions CD28 dependent PI3K/Akt signaling G alpha (q) signalling events GP1b-IX-V activation signalling VEGFA-VEGFR2 Pathway VEGFA-VEGFR2 Pathway Interleukin-3, Interleukin-5 and GM-CSF signaling Constitutive Signaling by EGFRvIII PI-3K cascade:FGFR1 PI-3K cascade:FGFR2 PI-3K cascade:FGFR3 PI-3K cascade:FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Signaling by FGFR3 in disease RAF/MAP kinase cascade Interleukin-4 and Interleukin-13 signaling PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling MET activates PI3K/AKT signaling RET signaling RHOA GTPase cycle Extra-nuclear estrogen signaling RHOB GTPase cycle RHOC GTPase cycle CDC42 GTPase cycle RAC1 GTPase cycle RAC2 GTPase cycle RHOD GTPase cycle RHOG GTPase cycle RHOJ GTPase cycle RHOU GTPase cycle RAC3 GTPase cycle RHOV GTPase cycle Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Activated NTRK2 signals through PI3K RHOF GTPase cycle Interleukin receptor SHC signaling Regulation of signaling by CBL Regulation of signaling by CBL Activated NTRK3 signals through PI3K FLT3 Signaling FLT3 Signaling Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants Signaling by CSF1 (M-CSF) in myeloid cells RND3 GTPase cycle RND2 GTPase cycle RND1 GTPase cycle Signaling by FLT3 fusion proteins Signaling by FLT3 fusion proteins Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants Signaling by ALK fusions and activated point mutants Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Signaling by LTK in cancer Signaling by LTK Co-stimulation by ICOS	Drugs 1 Imatinib Sunitinib Linifanib 5-CYANO-FURAN-2-CARBOXYLIC ACID [5-HYDROXYMETHYL-2-(4-METHYL-PIPERIDIN-1-YL)-PHENYL]-AMIDE 6-CHLORO-3-(3-METHYLISOXAZOL-5-YL)-4-PHENYLQUINOLIN-2(1H)-ONE Fostamatinib Erdafitinib Pexidartinib	Drugs 2 SF1126 Enzastaurin Wortmannin	Diseases 1 Choriocarcinoma	Diseases 2
Novel Novel	Symbols CSF1R and KIT	Name 1 colony stimulating factor 1 receptor	Name2 KIT proto-oncogene, receptor tyrosine kinase	Pathway 1 Other interleukin signaling Transcriptional Regulation by VENTX Signaling by CSF1 (M-CSF) in myeloid cells	Pathway 2 PIP3 activates AKT signaling Signaling by SCF-KIT Signaling by SCF-KIT Regulation of KIT signaling Regulation of KIT signaling Constitutive Signaling by Aberrant PI3K in Cancer RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Dasatinib-resistant KIT mutants Imatinib-resistant KIT mutants KIT mutants bind TKIs Masitinib-resistant KIT mutants Nilotinib-resistant KIT mutants Regorafenib-resistant KIT mutants Signaling by kinase domain mutants of KIT Sunitinib-resistant KIT mutants Signaling by juxtamembrane domain KIT mutants Sorafenib-resistant KIT mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by extracellular domain mutants of KIT Transcriptional and post-translational regulation of MITF-M expression and activity Developmental Lineage of Mammary Gland Luminal Epithelial Cells Developmental Lineage of Mammary Gland Alveolar Cells	Drugs 1 Imatinib Sunitinib Linifanib 5-CYANO-FURAN-2-CARBOXYLIC ACID [5-HYDROXYMETHYL-2-(4-METHYL-PIPERIDIN-1-YL)-PHENYL]-AMIDE 6-CHLORO-3-(3-METHYLISOXAZOL-5-YL)-4-PHENYLQUINOLIN-2(1H)-ONE Fostamatinib Erdafitinib Pexidartinib	Drugs 2 Sorafenib Imatinib Dasatinib Sunitinib Phosphonotyrosine Nilotinib XL820 OSI-930 Linifanib Pazopanib Midostaurin Regorafenib Ponatinib Lenvatinib Ancestim Tivozanib Fostamatinib Erdafitinib Amuvatinib Pexidartinib Ripretinib Avapritinib	Diseases 1 Choriocarcinoma	Diseases 2 Acute myeloid leukemia (AML) Piebaldism
Novel Novel	Symbols GRB2 and GAB2	Name 1 growth factor receptor bound protein 2	Name2 GRB2 associated binding protein 2	Pathway 1 Interleukin-15 signaling Interleukin-15 signaling Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants Signaling by ALK fusions and activated point mutants Signaling by LTK	Pathway 2 PI3K Cascade PIP3 activates AKT signaling Signaling by SCF-KIT Signaling by cytosolic FGFR1 fusion mutants Constitutive Signaling by Aberrant PI3K in Cancer Role of LAT2/NTAL/LAB on calcium mobilization Role of LAT2/NTAL/LAB on calcium mobilization PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling RET signaling Interleukin-15 signaling Interleukin receptor SHC signaling FLT3 Signaling FLT3 Signaling STAT5 Activation Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) Signaling by CSF1 (M-CSF) in myeloid cells STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 fusion proteins Signaling by FLT3 fusion proteins Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants	Drugs 1 Pegademase 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols GRB2 and SRC	Name 1 growth factor receptor bound protein 2	Name2 SRC proto-oncogene, non-receptor tyrosine kinase	Pathway 1 Interleukin-15 signaling Interleukin-15 signaling Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants Signaling by ALK fusions and activated point mutants Signaling by LTK	Pathway 2 Signaling by ERBB2 Nuclear signaling by ERBB4 Downregulation of ERBB4 signaling PIP3 activates AKT signaling GAB1 signalosome Downstream signal transduction Constitutive Signaling by Aberrant PI3K in Cancer Integrin signaling GRB2:SOS provides linkage to MAPK signaling for Integrins p130Cas linkage to MAPK signaling for integrins G alpha (s) signalling events G alpha (i) signalling events G alpha (i) signalling events DCC mediated attractive signaling DCC mediated attractive signaling Netrin mediated repulsion signals Regulation of commissural axon pathfinding by SLIT and ROBO RAF activation MAP2K and MAPK activation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling MET activates PTK2 signaling InlA-mediated entry of Listeria monocytogenes into host cells Regulation of RUNX1 Expression and Activity RUNX2 regulates osteoblast differentiation Regulation of RUNX3 expression and activity Extra-nuclear estrogen signaling RHOU GTPase cycle Activated NTRK2 signals through FYN Activated NTRK3 signals through PI3K Activated NTRK3 signals through PI3K Long-term potentiation GPER1 signaling Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by CSF1 (M-CSF) in myeloid cells Degradation of CDH1	Drugs 1 Pegademase 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid	Drugs 2 Dasatinib RU84687 RU79256 N6-Benzyl Adenosine-5'-Diphosphate RU85493 RU78262 Phosphonotyrosine Malonic acid RU83876 RU90395 RU79072 RU78783 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine PASBN 2-[4-[(Z)-2-Acetamido-3-oxo-3-[[(3S)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]amino]prop-1-enyl]-2-formylphenyl]acetic acid PAS219 DPI59 RU82197 Phenylphosphate RU78300 RU79073 RU82209 ISO24 RU85053 RU78299 Oxalic Acid RU78191 Citric acid Paratoulene phosphate 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE Purvalanol A XL228 Tirbanibulin Bosutinib 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL PD-168393 [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile PP-121 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide Ponatinib Nintedanib Fostamatinib	Diseases 1	Diseases 2
Novel Novel	Symbols GRB2 and VAV3	Name 1 growth factor receptor bound protein 2	Name2 vav guanine nucleotide exchange factor 3	Pathway 1 Interleukin-15 signaling Interleukin-15 signaling Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants Signaling by ALK fusions and activated point mutants Signaling by LTK	Pathway 2 GPVI-mediated activation cascade GPVI-mediated activation cascade NRAGE signals death through JNK Regulation of actin dynamics for phagocytic cup formation DAP12 signaling FCERI mediated MAPK activation FCERI mediated Ca+2 mobilization FCERI mediated Ca+2 mobilization EPH-ephrin mediated repulsion of cells G alpha (12/13) signalling events VEGFA-VEGFR2 Pathway VEGFA-VEGFR2 Pathway VEGFR2 mediated vascular permeability RHOA GTPase cycle CDC42 GTPase cycle RAC1 GTPase cycle RAC2 GTPase cycle RHOG GTPase cycle FCGR3A-mediated phagocytosis FCGR3A-mediated phagocytosis Azathioprine ADME	Drugs 1 Pegademase 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols GRB2 and KRT8	Name 1 growth factor receptor bound protein 2	Name2 keratin 8	Pathway 1 Interleukin-15 signaling Interleukin-15 signaling Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants Signaling by ALK fusions and activated point mutants Signaling by LTK	Pathway 2 Keratinization Formation of the cornified envelope Developmental Lineage of Mammary Gland Luminal Epithelial Cells Developmental Lineage of Mammary Gland Alveolar Cells	Drugs 1 Pegademase 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid	Drugs 2 Tenecteplase Lanoteplase Copper	Diseases 1	Diseases 2
Novel Novel	Symbols GRB2 and BCAR1	Name 1 growth factor receptor bound protein 2	Name2 BCAR1 scaffold protein, Cas family member	Pathway 1 Interleukin-15 signaling Interleukin-15 signaling Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants Signaling by ALK fusions and activated point mutants Signaling by LTK	Pathway 2 Downstream signal transduction p130Cas linkage to MAPK signaling for integrins VEGFA-VEGFR2 Pathway VEGFA-VEGFR2 Pathway PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases	Drugs 1 Pegademase 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols GRB2 and PDGFRB	Name 1 growth factor receptor bound protein 2	Name2 platelet derived growth factor receptor beta	Pathway 1 Interleukin-15 signaling Interleukin-15 signaling Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants Signaling by ALK fusions and activated point mutants Signaling by LTK	Pathway 2 PIP3 activates AKT signaling Downstream signal transduction Signaling by PDGF Constitutive Signaling by Aberrant PI3K in Cancer RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	Drugs 1 Pegademase 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid	Drugs 2 Becaplermin Sorafenib Imatinib Dasatinib Sunitinib XL999 XL820 Pazopanib Midostaurin Regorafenib Nintedanib Polaprezinc Trapidil Foreskin fibroblast (neonatal) Tivozanib Fostamatinib Erdafitinib Pexidartinib Ripretinib Pralsetinib	Diseases 1	Diseases 2 Glioma
Novel Novel	Symbols GRB2 and PTPN6	Name 1 growth factor receptor bound protein 2	Name2 protein tyrosine phosphatase non-receptor type 6	Pathway 1 Interleukin-15 signaling Interleukin-15 signaling Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants Signaling by ALK fusions and activated point mutants Signaling by LTK	Pathway 2 GPVI-mediated activation cascade Regulation of KIT signaling Signaling by ALK PECAM1 interactions Co-inhibition by PD-1 Signal regulatory protein family interactions Platelet sensitization by LDL Interleukin-3, Interleukin-5 and GM-CSF signaling CD22 mediated BCR regulation Neutrophil degranulation Interferon gamma signaling Regulation of IFNG signaling Interleukin-37 signaling Interferon alpha/beta signaling Interleukin receptor SHC signaling Regulation of IFNA/IFNB signaling SARS-CoV-2 activates/modulates innate and adaptive immune responses Nuclear events stimulated by ALK signaling in cancer Growth hormone receptor signaling Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Co-inhibition by BTLA	Drugs 1 Pegademase 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid	Drugs 2 Tiludronic acid	Diseases 1	Diseases 2
Novel Novel	Symbols GRB2 and PTPN11	Name 1 growth factor receptor bound protein 2	Name2 protein tyrosine phosphatase non-receptor type 11	Pathway 1 Interleukin-15 signaling Interleukin-15 signaling Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants Signaling by ALK fusions and activated point mutants Signaling by LTK	Pathway 2 Interleukin-6 signaling PI3K Cascade MAPK3 (ERK1) activation MAPK1 (ERK2) activation GPVI-mediated activation cascade Prolactin receptor signaling PIP3 activates AKT signaling Spry regulation of FGF signaling Signaling by SCF-KIT GAB1 signalosome Downstream signal transduction PECAM1 interactions Tie2 Signaling Constitutive Signaling by Aberrant PI3K in Cancer Signaling by Leptin Co-inhibition by CTLA4 Co-inhibition by PD-1 Signal regulatory protein family interactions Netrin mediated repulsion signals Platelet sensitization by LDL Interleukin-3, Interleukin-5 and GM-CSF signaling Interleukin-3, Interleukin-5 and GM-CSF signaling PI-3K cascade:FGFR1 FRS-mediated FGFR1 signaling PI-3K cascade:FGFR2 FRS-mediated FGFR2 signaling FRS-mediated FGFR3 signaling PI-3K cascade:FGFR3 FRS-mediated FGFR4 signaling PI-3K cascade:FGFR4 Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Regulation of IFNG signaling RET signaling Interleukin-20 family signaling MET activates PTPN11 Regulation of RUNX1 Expression and Activity Interleukin-37 signaling Activated NTRK2 signals through FRS2 and FRS3 Interferon alpha/beta signaling Regulation of IFNA/IFNB signaling Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) FLT3 Signaling STAT5 Activation Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) Signaling by CSF1 (M-CSF) in myeloid cells STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 ITD and TKD mutants SARS-CoV-2 activates/modulates innate and adaptive immune responses Co-inhibition by BTLA	Drugs 1 Pegademase 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid	Drugs 2 Dodecyltrimethylammonium	Diseases 1	Diseases 2 Metachondromatosis Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
Novel Novel	Symbols GRB2 and TNFRSF1A	Name 1 growth factor receptor bound protein 2	Name2 TNF receptor superfamily member 1A	Pathway 1 Interleukin-15 signaling Interleukin-15 signaling Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants Signaling by ALK fusions and activated point mutants Signaling by LTK	Pathway 2 TNFR1-induced proapoptotic signaling Regulation of TNFR1 signaling TNFR1-induced NF-kappa-B signaling pathway TNFR1-mediated ceramide production TNFs bind their physiological receptors Interleukin-10 signaling TNF signaling	Drugs 1 Pegademase 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid	Drugs 2 6-[3-(4-Morpholinyl)Propyl]-2-(3-Nitrophenyl)-5-Thioxo-5,6,-Dihydro-7h-Thienol[2',3':4,5]Pyrrolo[1,2-C]Imidazol-7-One Tasonermin	Diseases 1	Diseases 2 Tumor necrosis factor receptor-associated periodic syndrome (TRAPS); Familial periodic fever
Novel Novel	Symbols GRB2 and PLCG1	Name 1 growth factor receptor bound protein 2	Name2 phospholipase C gamma 1	Pathway 1 Interleukin-15 signaling Interleukin-15 signaling Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants Signaling by ALK fusions and activated point mutants Signaling by LTK	Pathway 2 ISG15 antiviral mechanism Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PLCG1 events in ERBB2 signaling DAG and IP3 signaling PLC-gamma1 signalling Synthesis of IP3 and IP4 in the cytosol Downstream signal transduction Signaling by ALK Generation of second messenger molecules Role of phospholipids in phagocytosis Role of phospholipids in phagocytosis PECAM1 interactions EGFR interacts with phospholipase C-gamma DAP12 signaling FCERI mediated MAPK activation FCERI mediated Ca+2 mobilization FCERI mediated Ca+2 mobilization Role of second messengers in netrin-1 signaling VEGFR2 mediated cell proliferation VEGFR2 mediated cell proliferation Constitutive Signaling by EGFRvIII Phospholipase C-mediated cascade: FGFR1 Phospholipase C-mediated cascade; FGFR2 Phospholipase C-mediated cascade; FGFR3 Phospholipase C-mediated cascade; FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Signaling by FGFR3 in disease RET signaling Activated NTRK2 signals through PLCG1 Activated NTRK2 signals through PLCG1 Erythropoietin activates Phospholipase C gamma (PLCG) Activated NTRK3 signals through PLCG1 Activated NTRK3 signals through PLCG1 FCGR3A-mediated IL10 synthesis Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Signaling by ALK fusions and activated point mutants	Drugs 1 Pegademase 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols GRB2 and NTRK1	Name 1 growth factor receptor bound protein 2	Name2 neurotrophic receptor tyrosine kinase 1	Pathway 1 Interleukin-15 signaling Interleukin-15 signaling Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants Signaling by ALK fusions and activated point mutants Signaling by LTK	Pathway 2 PLC-gamma1 signalling Signalling to RAS ARMS-mediated activation ARMS-mediated activation Retrograde neurotrophin signalling Retrograde neurotrophin signalling NGF-independant TRKA activation TRKA activation by NGF TRKA activation by NGF Signalling to p38 via RIT and RIN PI3K/AKT activation PI3K/AKT activation Signalling to STAT3	Drugs 1 Pegademase 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid	Drugs 2 Amitriptyline Imatinib Regorafenib Entrectinib Fostamatinib Cenegermin Larotrectinib Pralsetinib	Diseases 1	Diseases 2 Neuroblastoma Thyroid cancer
Novel Novel	Symbols GRB2 and PTPN1	Name 1 growth factor receptor bound protein 2	Name2 protein tyrosine phosphatase non-receptor type 1	Pathway 1 Interleukin-15 signaling Interleukin-15 signaling Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants Signaling by ALK fusions and activated point mutants Signaling by LTK	Pathway 2 Integrin signaling Negative regulation of MET activity Insulin receptor recycling Regulation of IFNG signaling PTK6 Down-Regulation MECP2 regulates neuronal receptors and channels Regulation of IFNA/IFNB signaling Growth hormone receptor signaling Growth hormone receptor signaling Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells	Drugs 1 Pegademase 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid	Drugs 2 3-(Oxalyl-Amino)-Naphthalene-2-Carboxylic Acid 2-{[4-(2-Acetylamino-2-pentylcarbamoyl-ethyl)-naphthalen-1-YL]-oxalyl-amino}-benzoic acid 5-(2-Fluoro-5-{(1E)-3-[3-hydroxy-2-(methoxycarbonyl)phenoxy]-1-propen-1-yl}phenyl)-1,2-oxazole-3-carboxylic acid 2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Thiopyran-3-Carboxylic Acid 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid (4-Sulfamoyl-Phenyl)-Amide [[4-(Aminomethyl)Phenyl]Amino]Oxo-Acetic Acid, {4-[(2S)-2-({[(1S)-1-Carboxy-2-phenylethyl]carbamoyl}amino)-3-oxo-3-(pentylamino)propyl]phenoxy}malonic acid Compound 19 3-(4-{2-[2-(2-bromo-acetylamino)-ethyldisulfanyl]-ethylcarbamoyl}-cyclohexylcarbamoyl)-pyrazine-2-carboxylic acid 2-(Oxalyl-Amino)-Benzoic Acid {[2-(1h-1,2,3-Benzotriazol-1-Yl)-2-(3,4-Difluorophenyl)Propane-1,3-Diyl]Bis[4,1-Phenylene(Difluoromethylene)]}Bis(Phosphonic Acid) Novo Nordisk a/S Compound N-(Bromoacetyl)-beta-alanyl-N-(2-{4-[(carboxycarbonyl)amino]phenyl}ethyl)-L-serinamide 7-(1,1-Dioxo-1h-Benzo[D]Isothiazol-3-Yloxymethyl)-2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Pyran-3-Carboxylic Acid PNU177836 2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Pyran-3-Carboxylic Acid {[7-(Difluoro-Phosphono-Methyl)-Naphthalen-2-Yl]-Difluoro-Methyl}-Phosphonic Acid 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid [4-(Thiazol-2-Ylsulfamoyl)-Phenyl]-Amide (4S)-5-[[(2S)-1-[[(2S)-1-Amino-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-4-benzamido-5-oxopentanoic acid 4-[[(2S)-1-[[6-[(1-Amino-1-oxo-3-sulfanylpropan-2-yl)amino]-6-oxohexyl]amino]-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-3-[[2-[4-[difluoro(phosphono)methyl]phenyl]acetyl]amino]-4-oxobutanoic acid L-cysteic acid 2-(Oxalyl-Amino)-4,5,6,7-Tetrahydro-Thieno[2,3-C]Pyridine-3-Carboxylic Acid -Carbonyl]-Amino}-Butyric Acid Compound 5, 2-(Naphthalen-1-Yl-Oxalyl-Amino)-Benzoicacid 6-(Oxalyl-Amino)-1h-Indole-5-Carboxylic Acid 2-[{4-[(2S)-2-{[(Allyloxy)carbonyl]amino}-3-({4-[3-hydroxy-2-(methoxycarbonyl)phenoxy]butyl}amino)-3-oxopropyl]phenyl}(carboxycarbonyl)amino]benzoic acid 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid Dimethylamide [(4-{4-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Butyl}-Phenyl)-Difluoro-Methyl]-Phosphonic Acid {4-[(2s,4e)-2-(1,3-Benzothiazol-2-Yl)-2-(1h-1,2,3-Benzotriazol-1-Yl)-5-Phenylpent-4-Enyl]Phenyl}(Difluoro)Methylphosphonic Acid N-(3-Carboxypropanoyl)-L-phenylalanyl-3-carboxy-O-(carboxymethyl)-N-pentyl-L-tyrosinamide 1-METHYL-3-PHENYL-1H-PYRAZOL-5-YLSULFAMIC ACID ISIS 113715 Trodusquemine Ertiprotafib 4-BROMO-3-(CARBOXYMETHOXY)-5-[3-(CYCLOHEXYLAMINO)PHENYL]THIOPHENE-2-CARBOXYLIC ACID [(3S)-3-(Methylcarbamoyl)-2-{[(2-methyl-2-propanyl)oxy]carbonyl}-1,2,3,4-tetrahydro-7-isoquinolinyl]sulfamic acid 4-BROMO-3-(CARBOXYMETHOXY)-5-PHENYLTHIOPHENE-2-CARBOXYLIC ACID 5-(4-CHLORO-5-PHENYL-3-THIENYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE 4-BROMO-3-(CARBOXYMETHOXY)-5-(4-HYDROXYPHENYL)THIOPHENE-2-CARBOXYLIC ACID [{2-bromo-4-[(2R)-3-oxo-2,3-diphenylpropyl]phenyl}(difluoro)methyl]phosphonic acid 5-[3-(BENZYLAMINO)PHENYL]-4-BROMO-3-(CARBOXYMETHOXY)THIOPHENE-2-CARBOXYLIC ACID 2-[(7-HYDROXY-NAPHTHALEN-1-YL)-OXALYL-AMINO]-BENZOIC ACID 3-(CARBOXYMETHOXY)THIENO[2,3-B]PYRIDINE-2-CARBOXYLIC ACID 4-PHOSPHONOOXY-PHENYL-METHYL-[4-PHOSPHONOOXY]BENZEN N-ACETYL-L-PHENYLALANYL-4-[DIFLUORO(PHOSPHONO)METHYL]-L-PHENYLALANINAMIDE [(3R)-3-(Methylcarbamoyl)-2-{[(2-methyl-2-propanyl)oxy]carbonyl}-1,2,3,4-tetrahydro-7-isoquinolinyl]sulfamic acid 5-(3-HYDROXYPHENYL)ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDE 5-(3-{3-[3-HYDROXY-2-(METHOXYCARBONYL)PHENOXY]PROPENYL}PHENYL)-4-(HYDROXYMETHYL)ISOXAZOLE-3-CARBOXYLIC ACID ISOTHIAZOLIDINONE ANALOG 4-[3-(dibenzylamino)phenyl]-2,4-dioxobutanoic acid p-Benzoyl-L-phenylalanine 6-(DIFLUORO-PHOSPHONO-METHYL)-NAPHTHALENE-2-CARBOXYLIC ACID (3R)-METHYLCARBAMOYL-7-SULFOAMINO-3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID BENZYL ESTER 5-(4-METHOXYBIPHENYL-3-YL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE 1,2,5-THIADIAZOLIDIN-3-ONE-1,1-DIOXIDE (4-{(2S)-2-[(tert-butoxycarbonyl)amino]-3-methoxy-3-oxopropyl}phenyl)methaneseleninic acid	Diseases 1	Diseases 2
Novel Novel	Symbols GRB2 and FRS2	Name 1 growth factor receptor bound protein 2	Name2 fibroblast growth factor receptor substrate 2	Pathway 1 Interleukin-15 signaling Interleukin-15 signaling Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants Signaling by ALK fusions and activated point mutants Signaling by LTK	Pathway 2 PI3K Cascade PIP3 activates AKT signaling Frs2-mediated activation Frs2-mediated activation Signaling by ALK Constitutive Signaling by Aberrant PI3K in Cancer PI-3K cascade:FGFR1 FRS-mediated FGFR1 signaling PI-3K cascade:FGFR2 FRS-mediated FGFR2 signaling FRS-mediated FGFR3 signaling PI-3K cascade:FGFR3 FRS-mediated FGFR4 signaling PI-3K cascade:FGFR4 Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Signaling by FGFR3 in disease RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling RET signaling Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK2 signals through FRS2 and FRS3 RND2 GTPase cycle RND1 GTPase cycle Signaling by ALK fusions and activated point mutants	Drugs 1 Pegademase 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols ARRB2 and CDC42	Name 1 arrestin beta 2	Name2 cell division cycle 42	Pathway 1 Activated NOTCH1 Transmits Signal to the Nucleus G alpha (s) signalling events Thrombin signalling through proteinase activated receptors (PARs) WNT5A-dependent internalization of FZD4 Activation of SMO Activation of SMO MAP2K and MAPK activation Ub-specific processing proteases Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis Signaling downstream of RAS mutants Signaling by RAF1 mutants TGFBR3 regulates TGF-beta signaling	Pathway 2 GPVI-mediated activation cascade EGFR downregulation Regulation of actin dynamics for phagocytic cup formation Regulation of actin dynamics for phagocytic cup formation CD28 dependent Vav1 pathway EPHB-mediated forward signaling EPHB-mediated forward signaling DCC mediated attractive signaling Inactivation of CDC42 and RAC1 VEGFA-VEGFR2 Pathway Myogenesis Myogenesis RHO GTPases activate KTN1 RHO GTPases activate IQGAPs RHO GTPases activate PAKs RHO GTPases Activate WASPs and WAVEs RHO GTPases Activate WASPs and WAVEs RHO GTPases Activate Formins RHO GTPases Activate Formins MAPK6/MAPK4 signaling Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation G beta:gamma signalling through CDC42 CDC42 GTPase cycle RAC1 GTPase cycle RAC2 GTPase cycle RHOQ GTPase cycle RHOG GTPase cycle RHOJ GTPase cycle RHOU GTPase cycle RAC3 GTPase cycle RHOV GTPase cycle FCGR3A-mediated phagocytosis FCGR3A-mediated phagocytosis Factors involved in megakaryocyte development and platelet production	Drugs 1	Drugs 2 Aminophosphonic acid-guanylate ester Guanosine-5'-Diphosphate	Diseases 1	Diseases 2
Novel	Symbols ARRB2 and BCAS1	Name 1 arrestin beta 2	Name2 brain enriched myelin associated protein 1	Pathway 1 Activated NOTCH1 Transmits Signal to the Nucleus G alpha (s) signalling events Thrombin signalling through proteinase activated receptors (PARs) WNT5A-dependent internalization of FZD4 Activation of SMO Activation of SMO MAP2K and MAPK activation Ub-specific processing proteases Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis Signaling downstream of RAS mutants Signaling by RAF1 mutants TGFBR3 regulates TGF-beta signaling	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols ARRB2 and CXCR4	Name 1 arrestin beta 2	Name2 C-X-C motif chemokine receptor 4	Pathway 1 Activated NOTCH1 Transmits Signal to the Nucleus G alpha (s) signalling events Thrombin signalling through proteinase activated receptors (PARs) WNT5A-dependent internalization of FZD4 Activation of SMO Activation of SMO MAP2K and MAPK activation Ub-specific processing proteases Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis Signaling downstream of RAS mutants Signaling by RAF1 mutants TGFBR3 regulates TGF-beta signaling	Pathway 2 Binding and entry of HIV virion Signaling by ROBO receptors Chemokine receptors bind chemokines G alpha (i) signalling events Formation of definitive endoderm Specification of primordial germ cells Developmental Lineage of Multipotent Pancreatic Progenitor Cells	Drugs 1	Drugs 2 Baclofen Framycetin AMD-070 Plerixafor Ulocuplumab Ibalizumab MSX-122	Diseases 1	Diseases 2 Chemokine receptor defect, including the following disease: WHIM syndrome
Novel	Symbols CSF1R and FYN	Name 1 colony stimulating factor 1 receptor	Name2 FYN proto-oncogene, Src family tyrosine kinase	Pathway 1 Other interleukin signaling Transcriptional Regulation by VENTX Signaling by CSF1 (M-CSF) in myeloid cells	Pathway 2 GPVI-mediated activation cascade Signaling by ERBB2 PIP3 activates AKT signaling Signaling by SCF-KIT Signaling by SCF-KIT Regulation of KIT signaling Nef and signal transduction Cell surface interactions at the vascular wall FCGR activation PECAM1 interactions Constitutive Signaling by Aberrant PI3K in Cancer DAP12 signaling DAP12 signaling EPH-Ephrin signaling Role of LAT2/NTAL/LAB on calcium mobilization Nephrin family interactions Nephrin family interactions NCAM signaling for neurite out-growth NCAM signaling for neurite out-growth Co-stimulation by CD28 CD28 dependent PI3K/Akt signaling CD28 dependent Vav1 pathway Co-inhibition by CTLA4 EPHB-mediated forward signaling EPHB-mediated forward signaling EPHA-mediated growth cone collapse EPHA-mediated growth cone collapse Ephrin signaling Ephrin signaling EPH-ephrin mediated repulsion of cells Sema3A PAK dependent Axon repulsion SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion CRMPs in Sema3A signaling CRMPs in Sema3A signaling VEGFA-VEGFR2 Pathway Dectin-2 family CD209 (DC-SIGN) signaling RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Platelet Adhesion to exposed collagen Reelin signalling pathway Regulation of signaling by CBL Regulation of signaling by CBL FCGR3A-mediated IL10 synthesis FCGR3A-mediated phagocytosis Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by CSF1 (M-CSF) in myeloid cells FLT3 signaling through SRC family kinases Antigen activates B Cell Receptor (BCR) leading to generation of second messengers High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells	Drugs 1 Imatinib Sunitinib Linifanib 5-CYANO-FURAN-2-CARBOXYLIC ACID [5-HYDROXYMETHYL-2-(4-METHYL-PIPERIDIN-1-YL)-PHENYL]-AMIDE 6-CHLORO-3-(3-METHYLISOXAZOL-5-YL)-4-PHENYLQUINOLIN-2(1H)-ONE Fostamatinib Erdafitinib Pexidartinib	Drugs 2 Dasatinib Triglyme Fostamatinib Zotiraciclib	Diseases 1 Choriocarcinoma	Diseases 2
Novel	Symbols CSF1R and SOS1	Name 1 colony stimulating factor 1 receptor	Name2 SOS Ras/Rac guanine nucleotide exchange factor 1	Pathway 1 Other interleukin signaling Transcriptional Regulation by VENTX Signaling by CSF1 (M-CSF) in myeloid cells	Pathway 2 SOS-mediated signalling SOS-mediated signalling Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants SHC1 events in ERBB2 signaling SHC1 events in ERBB4 signaling Signaling by SCF-KIT Regulation of KIT signaling Signalling to RAS Signalling to RAS GRB2 events in EGFR signaling SHC1 events in EGFR signaling Downstream signal transduction NRAGE signals death through JNK GRB2 events in ERBB2 signaling GRB2 events in ERBB2 signaling Tie2 Signaling EGFR Transactivation by Gastrin DAP12 signaling SHC-related events triggered by IGF1R SHC-related events triggered by IGF1R Role of LAT2/NTAL/LAB on calcium mobilization Role of LAT2/NTAL/LAB on calcium mobilization FCERI mediated MAPK activation FCERI mediated Ca+2 mobilization FCERI mediated Ca+2 mobilization GRB2:SOS provides linkage to MAPK signaling for Integrins NCAM signaling for neurite out-growth G alpha (12/13) signalling events Activation of RAC1 Constitutive Signaling by EGFRvIII SHC-mediated cascade:FGFR1 FRS-mediated FGFR1 signaling SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling SHC-mediated cascade:FGFR3 FRS-mediated FGFR3 signaling FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Signaling by FGFR3 in disease RAF/MAP kinase cascade Signal attenuation Insulin receptor signalling cascade Insulin receptor signalling cascade MET activates RAS signaling RET signaling Interleukin-15 signaling RAC1 GTPase cycle Activated NTRK2 signals through RAS Erythropoietin activates RAS Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK3 signals through RAS Interleukin receptor SHC signaling FLT3 Signaling Constitutive Signaling by Overexpressed ERBB2 Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants Potential therapeutics for SARS Signaling by CSF1 (M-CSF) in myeloid cells Signaling by FLT3 fusion proteins Signaling by FLT3 ITD and TKD mutants Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Signaling by LTK	Drugs 1 Imatinib Sunitinib Linifanib 5-CYANO-FURAN-2-CARBOXYLIC ACID [5-HYDROXYMETHYL-2-(4-METHYL-PIPERIDIN-1-YL)-PHENYL]-AMIDE 6-CHLORO-3-(3-METHYLISOXAZOL-5-YL)-4-PHENYLQUINOLIN-2(1H)-ONE Fostamatinib Erdafitinib Pexidartinib	Drugs 2	Diseases 1 Choriocarcinoma	Diseases 2 Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
Novel	Symbols CSF1R and PIK3R1	Name 1 colony stimulating factor 1 receptor	Name2 phosphoinositide-3-kinase regulatory subunit 1	Pathway 1 Other interleukin signaling Transcriptional Regulation by VENTX Signaling by CSF1 (M-CSF) in myeloid cells	Pathway 2 PI3K Cascade IRS-mediated signalling GPVI-mediated activation cascade Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K events in ERBB4 signaling PIP3 activates AKT signaling Interleukin-7 signaling Interleukin-7 signaling Signaling by SCF-KIT Synthesis of PIPs at the plasma membrane GAB1 signalosome Signaling by cytosolic FGFR1 fusion mutants Downstream signal transduction PI3K events in ERBB2 signaling PI3K/AKT activation Signaling by ALK Downstream TCR signaling Role of phospholipids in phagocytosis Tie2 Signaling Constitutive Signaling by Aberrant PI3K in Cancer DAP12 signaling Role of LAT2/NTAL/LAB on calcium mobilization Nephrin family interactions CD28 dependent PI3K/Akt signaling G alpha (q) signalling events GP1b-IX-V activation signalling VEGFA-VEGFR2 Pathway VEGFA-VEGFR2 Pathway Interleukin-3, Interleukin-5 and GM-CSF signaling Constitutive Signaling by EGFRvIII PI-3K cascade:FGFR1 PI-3K cascade:FGFR2 PI-3K cascade:FGFR3 PI-3K cascade:FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Signaling by FGFR3 in disease RAF/MAP kinase cascade Interleukin-4 and Interleukin-13 signaling PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling MET activates PI3K/AKT signaling RET signaling RHOA GTPase cycle Extra-nuclear estrogen signaling RHOB GTPase cycle RHOC GTPase cycle CDC42 GTPase cycle RAC1 GTPase cycle RAC2 GTPase cycle RHOD GTPase cycle RHOG GTPase cycle RHOJ GTPase cycle RHOU GTPase cycle RAC3 GTPase cycle RHOV GTPase cycle Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Activated NTRK2 signals through PI3K RHOF GTPase cycle Interleukin receptor SHC signaling Regulation of signaling by CBL Regulation of signaling by CBL Activated NTRK3 signals through PI3K FLT3 Signaling FLT3 Signaling Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants Signaling by CSF1 (M-CSF) in myeloid cells RND3 GTPase cycle RND2 GTPase cycle RND1 GTPase cycle Signaling by FLT3 fusion proteins Signaling by FLT3 fusion proteins Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants Signaling by ALK fusions and activated point mutants Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Signaling by LTK in cancer Signaling by LTK Co-stimulation by ICOS	Drugs 1 Imatinib Sunitinib Linifanib 5-CYANO-FURAN-2-CARBOXYLIC ACID [5-HYDROXYMETHYL-2-(4-METHYL-PIPERIDIN-1-YL)-PHENYL]-AMIDE 6-CHLORO-3-(3-METHYLISOXAZOL-5-YL)-4-PHENYLQUINOLIN-2(1H)-ONE Fostamatinib Erdafitinib Pexidartinib	Drugs 2 SF1126 Enzastaurin Wortmannin	Diseases 1 Choriocarcinoma	Diseases 2
Novel	Symbols CSF1R and KIT	Name 1 colony stimulating factor 1 receptor	Name2 KIT proto-oncogene, receptor tyrosine kinase	Pathway 1 Other interleukin signaling Transcriptional Regulation by VENTX Signaling by CSF1 (M-CSF) in myeloid cells	Pathway 2 PIP3 activates AKT signaling Signaling by SCF-KIT Signaling by SCF-KIT Regulation of KIT signaling Regulation of KIT signaling Constitutive Signaling by Aberrant PI3K in Cancer RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Dasatinib-resistant KIT mutants Imatinib-resistant KIT mutants KIT mutants bind TKIs Masitinib-resistant KIT mutants Nilotinib-resistant KIT mutants Regorafenib-resistant KIT mutants Signaling by kinase domain mutants of KIT Sunitinib-resistant KIT mutants Signaling by juxtamembrane domain KIT mutants Sorafenib-resistant KIT mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by extracellular domain mutants of KIT Transcriptional and post-translational regulation of MITF-M expression and activity Developmental Lineage of Mammary Gland Luminal Epithelial Cells Developmental Lineage of Mammary Gland Alveolar Cells	Drugs 1 Imatinib Sunitinib Linifanib 5-CYANO-FURAN-2-CARBOXYLIC ACID [5-HYDROXYMETHYL-2-(4-METHYL-PIPERIDIN-1-YL)-PHENYL]-AMIDE 6-CHLORO-3-(3-METHYLISOXAZOL-5-YL)-4-PHENYLQUINOLIN-2(1H)-ONE Fostamatinib Erdafitinib Pexidartinib	Drugs 2 Sorafenib Imatinib Dasatinib Sunitinib Phosphonotyrosine Nilotinib XL820 OSI-930 Linifanib Pazopanib Midostaurin Regorafenib Ponatinib Lenvatinib Ancestim Tivozanib Fostamatinib Erdafitinib Amuvatinib Pexidartinib Ripretinib Avapritinib	Diseases 1 Choriocarcinoma	Diseases 2 Acute myeloid leukemia (AML) Piebaldism
Novel	Symbols GRB2 and GAB2	Name 1 growth factor receptor bound protein 2	Name2 GRB2 associated binding protein 2	Pathway 1 Interleukin-15 signaling Interleukin-15 signaling Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants Signaling by ALK fusions and activated point mutants Signaling by LTK	Pathway 2 PI3K Cascade PIP3 activates AKT signaling Signaling by SCF-KIT Signaling by cytosolic FGFR1 fusion mutants Constitutive Signaling by Aberrant PI3K in Cancer Role of LAT2/NTAL/LAB on calcium mobilization Role of LAT2/NTAL/LAB on calcium mobilization PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling RET signaling Interleukin-15 signaling Interleukin receptor SHC signaling FLT3 Signaling FLT3 Signaling STAT5 Activation Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) Signaling by CSF1 (M-CSF) in myeloid cells STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 fusion proteins Signaling by FLT3 fusion proteins Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants	Drugs 1 Pegademase 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols GRB2 and SRC	Name 1 growth factor receptor bound protein 2	Name2 SRC proto-oncogene, non-receptor tyrosine kinase	Pathway 1 Interleukin-15 signaling Interleukin-15 signaling Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants Signaling by ALK fusions and activated point mutants Signaling by LTK	Pathway 2 Signaling by ERBB2 Nuclear signaling by ERBB4 Downregulation of ERBB4 signaling PIP3 activates AKT signaling GAB1 signalosome Downstream signal transduction Constitutive Signaling by Aberrant PI3K in Cancer Integrin signaling GRB2:SOS provides linkage to MAPK signaling for Integrins p130Cas linkage to MAPK signaling for integrins G alpha (s) signalling events G alpha (i) signalling events G alpha (i) signalling events DCC mediated attractive signaling DCC mediated attractive signaling Netrin mediated repulsion signals Regulation of commissural axon pathfinding by SLIT and ROBO RAF activation MAP2K and MAPK activation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling MET activates PTK2 signaling InlA-mediated entry of Listeria monocytogenes into host cells Regulation of RUNX1 Expression and Activity RUNX2 regulates osteoblast differentiation Regulation of RUNX3 expression and activity Extra-nuclear estrogen signaling RHOU GTPase cycle Activated NTRK2 signals through FYN Activated NTRK3 signals through PI3K Activated NTRK3 signals through PI3K Long-term potentiation GPER1 signaling Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by CSF1 (M-CSF) in myeloid cells Degradation of CDH1	Drugs 1 Pegademase 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid	Drugs 2 Dasatinib RU84687 RU79256 N6-Benzyl Adenosine-5'-Diphosphate RU85493 RU78262 Phosphonotyrosine Malonic acid RU83876 RU90395 RU79072 RU78783 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine PASBN 2-[4-[(Z)-2-Acetamido-3-oxo-3-[[(3S)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]amino]prop-1-enyl]-2-formylphenyl]acetic acid PAS219 DPI59 RU82197 Phenylphosphate RU78300 RU79073 RU82209 ISO24 RU85053 RU78299 Oxalic Acid RU78191 Citric acid Paratoulene phosphate 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE Purvalanol A XL228 Tirbanibulin Bosutinib 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL PD-168393 [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile PP-121 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide Ponatinib Nintedanib Fostamatinib	Diseases 1	Diseases 2
Novel	Symbols GRB2 and VAV3	Name 1 growth factor receptor bound protein 2	Name2 vav guanine nucleotide exchange factor 3	Pathway 1 Interleukin-15 signaling Interleukin-15 signaling Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants Signaling by ALK fusions and activated point mutants Signaling by LTK	Pathway 2 GPVI-mediated activation cascade GPVI-mediated activation cascade NRAGE signals death through JNK Regulation of actin dynamics for phagocytic cup formation DAP12 signaling FCERI mediated MAPK activation FCERI mediated Ca+2 mobilization FCERI mediated Ca+2 mobilization EPH-ephrin mediated repulsion of cells G alpha (12/13) signalling events VEGFA-VEGFR2 Pathway VEGFA-VEGFR2 Pathway VEGFR2 mediated vascular permeability RHOA GTPase cycle CDC42 GTPase cycle RAC1 GTPase cycle RAC2 GTPase cycle RHOG GTPase cycle FCGR3A-mediated phagocytosis FCGR3A-mediated phagocytosis Azathioprine ADME	Drugs 1 Pegademase 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols GRB2 and KRT8	Name 1 growth factor receptor bound protein 2	Name2 keratin 8	Pathway 1 Interleukin-15 signaling Interleukin-15 signaling Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants Signaling by ALK fusions and activated point mutants Signaling by LTK	Pathway 2 Keratinization Formation of the cornified envelope Developmental Lineage of Mammary Gland Luminal Epithelial Cells Developmental Lineage of Mammary Gland Alveolar Cells	Drugs 1 Pegademase 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid	Drugs 2 Tenecteplase Lanoteplase Copper	Diseases 1	Diseases 2
Novel	Symbols GRB2 and BCAR1	Name 1 growth factor receptor bound protein 2	Name2 BCAR1 scaffold protein, Cas family member	Pathway 1 Interleukin-15 signaling Interleukin-15 signaling Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants Signaling by ALK fusions and activated point mutants Signaling by LTK	Pathway 2 Downstream signal transduction p130Cas linkage to MAPK signaling for integrins VEGFA-VEGFR2 Pathway VEGFA-VEGFR2 Pathway PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases	Drugs 1 Pegademase 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols GRB2 and PDGFRB	Name 1 growth factor receptor bound protein 2	Name2 platelet derived growth factor receptor beta	Pathway 1 Interleukin-15 signaling Interleukin-15 signaling Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants Signaling by ALK fusions and activated point mutants Signaling by LTK	Pathway 2 PIP3 activates AKT signaling Downstream signal transduction Signaling by PDGF Constitutive Signaling by Aberrant PI3K in Cancer RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	Drugs 1 Pegademase 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid	Drugs 2 Becaplermin Sorafenib Imatinib Dasatinib Sunitinib XL999 XL820 Pazopanib Midostaurin Regorafenib Nintedanib Polaprezinc Trapidil Foreskin fibroblast (neonatal) Tivozanib Fostamatinib Erdafitinib Pexidartinib Ripretinib Pralsetinib	Diseases 1	Diseases 2 Glioma
Novel	Symbols GRB2 and PTPN6	Name 1 growth factor receptor bound protein 2	Name2 protein tyrosine phosphatase non-receptor type 6	Pathway 1 Interleukin-15 signaling Interleukin-15 signaling Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants Signaling by ALK fusions and activated point mutants Signaling by LTK	Pathway 2 GPVI-mediated activation cascade Regulation of KIT signaling Signaling by ALK PECAM1 interactions Co-inhibition by PD-1 Signal regulatory protein family interactions Platelet sensitization by LDL Interleukin-3, Interleukin-5 and GM-CSF signaling CD22 mediated BCR regulation Neutrophil degranulation Interferon gamma signaling Regulation of IFNG signaling Interleukin-37 signaling Interferon alpha/beta signaling Interleukin receptor SHC signaling Regulation of IFNA/IFNB signaling SARS-CoV-2 activates/modulates innate and adaptive immune responses Nuclear events stimulated by ALK signaling in cancer Growth hormone receptor signaling Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Co-inhibition by BTLA	Drugs 1 Pegademase 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid	Drugs 2 Tiludronic acid	Diseases 1	Diseases 2
Novel	Symbols GRB2 and PTPN11	Name 1 growth factor receptor bound protein 2	Name2 protein tyrosine phosphatase non-receptor type 11	Pathway 1 Interleukin-15 signaling Interleukin-15 signaling Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants Signaling by ALK fusions and activated point mutants Signaling by LTK	Pathway 2 Interleukin-6 signaling PI3K Cascade MAPK3 (ERK1) activation MAPK1 (ERK2) activation GPVI-mediated activation cascade Prolactin receptor signaling PIP3 activates AKT signaling Spry regulation of FGF signaling Signaling by SCF-KIT GAB1 signalosome Downstream signal transduction PECAM1 interactions Tie2 Signaling Constitutive Signaling by Aberrant PI3K in Cancer Signaling by Leptin Co-inhibition by CTLA4 Co-inhibition by PD-1 Signal regulatory protein family interactions Netrin mediated repulsion signals Platelet sensitization by LDL Interleukin-3, Interleukin-5 and GM-CSF signaling Interleukin-3, Interleukin-5 and GM-CSF signaling PI-3K cascade:FGFR1 FRS-mediated FGFR1 signaling PI-3K cascade:FGFR2 FRS-mediated FGFR2 signaling FRS-mediated FGFR3 signaling PI-3K cascade:FGFR3 FRS-mediated FGFR4 signaling PI-3K cascade:FGFR4 Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Regulation of IFNG signaling RET signaling Interleukin-20 family signaling MET activates PTPN11 Regulation of RUNX1 Expression and Activity Interleukin-37 signaling Activated NTRK2 signals through FRS2 and FRS3 Interferon alpha/beta signaling Regulation of IFNA/IFNB signaling Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) FLT3 Signaling STAT5 Activation Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) Signaling by CSF1 (M-CSF) in myeloid cells STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 ITD and TKD mutants SARS-CoV-2 activates/modulates innate and adaptive immune responses Co-inhibition by BTLA	Drugs 1 Pegademase 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid	Drugs 2 Dodecyltrimethylammonium	Diseases 1	Diseases 2 Metachondromatosis Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
Novel	Symbols GRB2 and TNFRSF1A	Name 1 growth factor receptor bound protein 2	Name2 TNF receptor superfamily member 1A	Pathway 1 Interleukin-15 signaling Interleukin-15 signaling Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants Signaling by ALK fusions and activated point mutants Signaling by LTK	Pathway 2 TNFR1-induced proapoptotic signaling Regulation of TNFR1 signaling TNFR1-induced NF-kappa-B signaling pathway TNFR1-mediated ceramide production TNFs bind their physiological receptors Interleukin-10 signaling TNF signaling	Drugs 1 Pegademase 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid	Drugs 2 6-[3-(4-Morpholinyl)Propyl]-2-(3-Nitrophenyl)-5-Thioxo-5,6,-Dihydro-7h-Thienol[2',3':4,5]Pyrrolo[1,2-C]Imidazol-7-One Tasonermin	Diseases 1	Diseases 2 Tumor necrosis factor receptor-associated periodic syndrome (TRAPS); Familial periodic fever
Novel	Symbols GRB2 and PLCG1	Name 1 growth factor receptor bound protein 2	Name2 phospholipase C gamma 1	Pathway 1 Interleukin-15 signaling Interleukin-15 signaling Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants Signaling by ALK fusions and activated point mutants Signaling by LTK	Pathway 2 ISG15 antiviral mechanism Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PLCG1 events in ERBB2 signaling DAG and IP3 signaling PLC-gamma1 signalling Synthesis of IP3 and IP4 in the cytosol Downstream signal transduction Signaling by ALK Generation of second messenger molecules Role of phospholipids in phagocytosis Role of phospholipids in phagocytosis PECAM1 interactions EGFR interacts with phospholipase C-gamma DAP12 signaling FCERI mediated MAPK activation FCERI mediated Ca+2 mobilization FCERI mediated Ca+2 mobilization Role of second messengers in netrin-1 signaling VEGFR2 mediated cell proliferation VEGFR2 mediated cell proliferation Constitutive Signaling by EGFRvIII Phospholipase C-mediated cascade: FGFR1 Phospholipase C-mediated cascade; FGFR2 Phospholipase C-mediated cascade; FGFR3 Phospholipase C-mediated cascade; FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Signaling by FGFR3 in disease RET signaling Activated NTRK2 signals through PLCG1 Activated NTRK2 signals through PLCG1 Erythropoietin activates Phospholipase C gamma (PLCG) Activated NTRK3 signals through PLCG1 Activated NTRK3 signals through PLCG1 FCGR3A-mediated IL10 synthesis Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Signaling by ALK fusions and activated point mutants	Drugs 1 Pegademase 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols GRB2 and NTRK1	Name 1 growth factor receptor bound protein 2	Name2 neurotrophic receptor tyrosine kinase 1	Pathway 1 Interleukin-15 signaling Interleukin-15 signaling Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants Signaling by ALK fusions and activated point mutants Signaling by LTK	Pathway 2 PLC-gamma1 signalling Signalling to RAS ARMS-mediated activation ARMS-mediated activation Retrograde neurotrophin signalling Retrograde neurotrophin signalling NGF-independant TRKA activation TRKA activation by NGF TRKA activation by NGF Signalling to p38 via RIT and RIN PI3K/AKT activation PI3K/AKT activation Signalling to STAT3	Drugs 1 Pegademase 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid	Drugs 2 Amitriptyline Imatinib Regorafenib Entrectinib Fostamatinib Cenegermin Larotrectinib Pralsetinib	Diseases 1	Diseases 2 Neuroblastoma Thyroid cancer
Novel	Symbols GRB2 and PTPN1	Name 1 growth factor receptor bound protein 2	Name2 protein tyrosine phosphatase non-receptor type 1	Pathway 1 Interleukin-15 signaling Interleukin-15 signaling Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants Signaling by ALK fusions and activated point mutants Signaling by LTK	Pathway 2 Integrin signaling Negative regulation of MET activity Insulin receptor recycling Regulation of IFNG signaling PTK6 Down-Regulation MECP2 regulates neuronal receptors and channels Regulation of IFNA/IFNB signaling Growth hormone receptor signaling Growth hormone receptor signaling Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells	Drugs 1 Pegademase 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid	Drugs 2 3-(Oxalyl-Amino)-Naphthalene-2-Carboxylic Acid 2-{[4-(2-Acetylamino-2-pentylcarbamoyl-ethyl)-naphthalen-1-YL]-oxalyl-amino}-benzoic acid 5-(2-Fluoro-5-{(1E)-3-[3-hydroxy-2-(methoxycarbonyl)phenoxy]-1-propen-1-yl}phenyl)-1,2-oxazole-3-carboxylic acid 2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Thiopyran-3-Carboxylic Acid 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid (4-Sulfamoyl-Phenyl)-Amide [[4-(Aminomethyl)Phenyl]Amino]Oxo-Acetic Acid, {4-[(2S)-2-({[(1S)-1-Carboxy-2-phenylethyl]carbamoyl}amino)-3-oxo-3-(pentylamino)propyl]phenoxy}malonic acid Compound 19 3-(4-{2-[2-(2-bromo-acetylamino)-ethyldisulfanyl]-ethylcarbamoyl}-cyclohexylcarbamoyl)-pyrazine-2-carboxylic acid 2-(Oxalyl-Amino)-Benzoic Acid {[2-(1h-1,2,3-Benzotriazol-1-Yl)-2-(3,4-Difluorophenyl)Propane-1,3-Diyl]Bis[4,1-Phenylene(Difluoromethylene)]}Bis(Phosphonic Acid) Novo Nordisk a/S Compound N-(Bromoacetyl)-beta-alanyl-N-(2-{4-[(carboxycarbonyl)amino]phenyl}ethyl)-L-serinamide 7-(1,1-Dioxo-1h-Benzo[D]Isothiazol-3-Yloxymethyl)-2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Pyran-3-Carboxylic Acid PNU177836 2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Pyran-3-Carboxylic Acid {[7-(Difluoro-Phosphono-Methyl)-Naphthalen-2-Yl]-Difluoro-Methyl}-Phosphonic Acid 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid [4-(Thiazol-2-Ylsulfamoyl)-Phenyl]-Amide (4S)-5-[[(2S)-1-[[(2S)-1-Amino-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-4-benzamido-5-oxopentanoic acid 4-[[(2S)-1-[[6-[(1-Amino-1-oxo-3-sulfanylpropan-2-yl)amino]-6-oxohexyl]amino]-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-3-[[2-[4-[difluoro(phosphono)methyl]phenyl]acetyl]amino]-4-oxobutanoic acid L-cysteic acid 2-(Oxalyl-Amino)-4,5,6,7-Tetrahydro-Thieno[2,3-C]Pyridine-3-Carboxylic Acid -Carbonyl]-Amino}-Butyric Acid Compound 5, 2-(Naphthalen-1-Yl-Oxalyl-Amino)-Benzoicacid 6-(Oxalyl-Amino)-1h-Indole-5-Carboxylic Acid 2-[{4-[(2S)-2-{[(Allyloxy)carbonyl]amino}-3-({4-[3-hydroxy-2-(methoxycarbonyl)phenoxy]butyl}amino)-3-oxopropyl]phenyl}(carboxycarbonyl)amino]benzoic acid 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid Dimethylamide [(4-{4-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Butyl}-Phenyl)-Difluoro-Methyl]-Phosphonic Acid {4-[(2s,4e)-2-(1,3-Benzothiazol-2-Yl)-2-(1h-1,2,3-Benzotriazol-1-Yl)-5-Phenylpent-4-Enyl]Phenyl}(Difluoro)Methylphosphonic Acid N-(3-Carboxypropanoyl)-L-phenylalanyl-3-carboxy-O-(carboxymethyl)-N-pentyl-L-tyrosinamide 1-METHYL-3-PHENYL-1H-PYRAZOL-5-YLSULFAMIC ACID ISIS 113715 Trodusquemine Ertiprotafib 4-BROMO-3-(CARBOXYMETHOXY)-5-[3-(CYCLOHEXYLAMINO)PHENYL]THIOPHENE-2-CARBOXYLIC ACID [(3S)-3-(Methylcarbamoyl)-2-{[(2-methyl-2-propanyl)oxy]carbonyl}-1,2,3,4-tetrahydro-7-isoquinolinyl]sulfamic acid 4-BROMO-3-(CARBOXYMETHOXY)-5-PHENYLTHIOPHENE-2-CARBOXYLIC ACID 5-(4-CHLORO-5-PHENYL-3-THIENYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE 4-BROMO-3-(CARBOXYMETHOXY)-5-(4-HYDROXYPHENYL)THIOPHENE-2-CARBOXYLIC ACID [{2-bromo-4-[(2R)-3-oxo-2,3-diphenylpropyl]phenyl}(difluoro)methyl]phosphonic acid 5-[3-(BENZYLAMINO)PHENYL]-4-BROMO-3-(CARBOXYMETHOXY)THIOPHENE-2-CARBOXYLIC ACID 2-[(7-HYDROXY-NAPHTHALEN-1-YL)-OXALYL-AMINO]-BENZOIC ACID 3-(CARBOXYMETHOXY)THIENO[2,3-B]PYRIDINE-2-CARBOXYLIC ACID 4-PHOSPHONOOXY-PHENYL-METHYL-[4-PHOSPHONOOXY]BENZEN N-ACETYL-L-PHENYLALANYL-4-[DIFLUORO(PHOSPHONO)METHYL]-L-PHENYLALANINAMIDE [(3R)-3-(Methylcarbamoyl)-2-{[(2-methyl-2-propanyl)oxy]carbonyl}-1,2,3,4-tetrahydro-7-isoquinolinyl]sulfamic acid 5-(3-HYDROXYPHENYL)ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDE 5-(3-{3-[3-HYDROXY-2-(METHOXYCARBONYL)PHENOXY]PROPENYL}PHENYL)-4-(HYDROXYMETHYL)ISOXAZOLE-3-CARBOXYLIC ACID ISOTHIAZOLIDINONE ANALOG 4-[3-(dibenzylamino)phenyl]-2,4-dioxobutanoic acid p-Benzoyl-L-phenylalanine 6-(DIFLUORO-PHOSPHONO-METHYL)-NAPHTHALENE-2-CARBOXYLIC ACID (3R)-METHYLCARBAMOYL-7-SULFOAMINO-3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID BENZYL ESTER 5-(4-METHOXYBIPHENYL-3-YL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE 1,2,5-THIADIAZOLIDIN-3-ONE-1,1-DIOXIDE (4-{(2S)-2-[(tert-butoxycarbonyl)amino]-3-methoxy-3-oxopropyl}phenyl)methaneseleninic acid	Diseases 1	Diseases 2
Novel	Symbols GRB2 and FRS2	Name 1 growth factor receptor bound protein 2	Name2 fibroblast growth factor receptor substrate 2	Pathway 1 Interleukin-15 signaling Interleukin-15 signaling Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants Signaling by ALK fusions and activated point mutants Signaling by LTK	Pathway 2 PI3K Cascade PIP3 activates AKT signaling Frs2-mediated activation Frs2-mediated activation Signaling by ALK Constitutive Signaling by Aberrant PI3K in Cancer PI-3K cascade:FGFR1 FRS-mediated FGFR1 signaling PI-3K cascade:FGFR2 FRS-mediated FGFR2 signaling FRS-mediated FGFR3 signaling PI-3K cascade:FGFR3 FRS-mediated FGFR4 signaling PI-3K cascade:FGFR4 Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Signaling by FGFR3 in disease RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling RET signaling Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK2 signals through FRS2 and FRS3 RND2 GTPase cycle RND1 GTPase cycle Signaling by ALK fusions and activated point mutants	Drugs 1 Pegademase 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid	Drugs 2	Diseases 1	Diseases 2

Page 23 out of 98 pages

Search Results : Cancer